Corporate venturing unit Amgen Ventures contributed to a $25.5m funding round for the microfluidics healthcare technology developer.

Startups with fewer than 500 employees will be able to apply for loans of up to $10m from the US government's $350bn Paycheck Protection Program.

Cowen and European Investment Bank added $52m to a $130m first tranche closed by the AbbVie and Pfizer-backed kidney injury drug developer in July.

The WuXi-backed investment firm returned for a series B2 round that will support phase 1/2 trials for iTeos Therapeutics' oncology therapies.

Autoimmune disease drug developer Pandion Therapeutics closed a series B round co-led by Access Biotechnology and backed by Roche Venture Fund and SR One.

CapitalG returned for a late-stage round that pushed Collibra’s total funding beyond $345m and boosted its valuation to $2.3bn.

The Parkinson's disease therapy developer closed the series A funding less than four months after a Eurofarma-backed seed round.

The enterprise communication platform developer has now raised more than $62m altogether, Dell Technologies Capital leading its latest round.

Galijasevic predicts collaborations among corporate VCs and startups will only accelerate as they look to innovative technologies to address customer needs during tumultuous times.

Early investors and employees were set to benefit from a $3bn tender offer for the troubled workspace provider but key investor SoftBank has pulled out.